An­sun Bio­phar­ma clos­es $80M Se­ries B; Red­Hill Bio­phar­ma ties up with Cos­mo Phar­ma­ceu­ti­cals

→ San Diego-based An­sun Bio­phar­ma re­cent­ly closed an $80 mil­lion Se­ries B fund­ing round, led by Chi­na In­vestors, ac­cord­ing to Chin­aBio To­day. The funds will be used to help ad­vance the com­pa­ny’s lead an­tivi­ral, which al­ready been grant­ed fast track el­i­gi­bil­i­ty and break­through ther­a­py sta­tus by the FDA in the US and is be­ing re­viewed for the treat­ment of low­er res­pi­ra­to­ry tract in­fec­tions caused by parain­fluen­za virus (PIV) in im­mun­od­e­fi­cient pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.